Minerva starts phase 3 trial for schizophrenia drug roluperidone

March 31, 2026 4:05 PM

Minerva Neurosciences Inc. (NASDAQ: NERV) announced that the first patient has been screened in its global Phase 3 confirmatory trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found